Cedrik M. Britten
Chief Tech/Sci/R&D Officer at IMMATICS N.V.
Net worth: 2 M $ as of 30/03/2024
Profile
Cedrik M.
Britten is currently the Chief Medical Officer at Immatics Biotechnologies GmbH and Immatics NV.
Prior to his current positions, he worked as the VP & Head-Oncology Cell Therapy Research at GSK Plc from 2015 to 2020 and as the Vice President-Research & Development at BioNTech RNA Pharmaceuticals GmbH from 2010 to 2015.
Britten received his graduate and doctorate degrees from The Johannes Gutenberg University of Mainz.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMATICS N.V.
0.22% | 30/01/2024 | 227,735 ( 0.22% ) | 2 M $ | 30/03/2024 |
Cedrik M. Britten active positions
| Companies | Position | Start |
|---|---|---|
| IMMATICS N.V. | Chief Tech/Sci/R&D Officer | 31/05/2020 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 31/05/2020 |
Former positions of Cedrik M. Britten
| Companies | Position | End |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 30/04/2020 |
BioNTech RNA Pharmaceuticals GmbH
 BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Chief Tech/Sci/R&D Officer | 31/12/2014 |
Training of Cedrik M. Britten
| The Johannes Gutenberg University of Mainz | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GSK PLC | Health Technology |
| IMMATICS N.V. | Health Technology |
| Private companies | 2 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
BioNTech RNA Pharmaceuticals GmbH
BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Health Technology |
- Stock Market
- Insiders
- Cedrik M. Britten
